Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Lancet (London, England)|December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The Lancet. HIV|May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trialIan Frank, Shuying S Li, Nicole Grunenberg, et al.
JACC. Advances|June 28, 2024
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk PopulationsJulia Karady, Michael T Lu, Göran Bergström, et al.
JAMA Cardiology|February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical TrialMichael T Lu, Heather Ribaudo, Borek Foldyna, et al.
The New England Journal of Medicine|July 24, 2023
Pitavastatin to Prevent Cardiovascular Disease in HIV InfectionSteven K Grinspoon, Kathleen V Fitch, Markella V Zanni, et al.
Transboundary and Emerging Diseases|April 30, 2025
Mitigating Risk: Predicting H5N1 Avian Influenza Spread with an Empirical Model of Bird MovementFiona McDuie, Cory T Overton, Austen A Lorenz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 2, 2020
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR TrialsGiuliano Rizzardini, Edgar T Overton, Chloe Orkin, et al.
The New England Journal of Medicine|December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment InterruptionKatharine J Bar, Michael C Sneller, Linda J Harrison, et al.
The Western Journal of Emergency Medicine|August 12, 2025
Letter of Concern from the Association of Academic Chairs of Emergency Medicine Regarding ACGME Proposed ChangesRichard J Hamilton, Lance B Becker, Richard E Wolfe, et al.
The New England Journal of Medicine|August 11, 2021
Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J Landovitz, Deborah Donnell, Meredith E Clement, et al.
Pageof 17